Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Discovers Explosive Properties of Togni Reagent II

Published: Wednesday, April 17, 2013
Last Updated: Wednesday, April 17, 2013
Bookmark and Share
Novasep reclassifies reagent and informs market about new safety measures required.

Novasep has announced that its R&D team has discovered and characterized the explosive properties of the Togni reagent II and intermediates at the Novasep Leverkusen site in Germany.

The findings have been published in the March edition of the journal Organic Process Research and Development.

Togni reagent II (1-(trifluoromethyl)-1,2-benziodoxol-3(1H)-one, 1) is a versatile reagent for the electrophilic introduction of trifluoromethyl groups. It is used in pharmaceutical manufacturing. It is also widely used in universities.

Novasep conducted a Koenen test on a sample of Togni Reagent II prepared in their kilolab, in which the reagent was shown to be highly explosive.

Another critical property of the Togni Reagent II clarified by the Novasep team is its fast combustion when ignited. The combustion factor was measured as BZ6, the same classification as black powder.

This discovery has resulted in a revised classification for handling and transportation of the Togni reagent II, which must now be approved by national competent authorities.

Novasep has also informed companies known to market the compound, who will relay the safety measures required to handle the reagent.

Tests were conducted in the Novasep Leverkusen plant. The plant has German government authorization to handle energetic materials and operate hazardous reactions from lab to thousands tons scale.

This has enabled Novasep to develop reliable and cost-efficient processes that satisfy regulatory requirements whilst maintaining safety for technical staff and its plants.

The skill developed by Novasep includes managing large-scale reactions that use sodium azide, reactive metals, diazomethane and diborane (both in gaseous form), hydrazine, ozone and nitroalkanes.

These chemical reactions are often more direct and cost-efficient than traditional routes of synthesis. They generally create fewer by-products and have a high yield and productivity.

“Novasep has used our 140 years experience and the knowledge of our R&D team in highly energetic reagents and reactions as well as our specialized equipment to be able to identify another set of dangerous properties of a commonly used compound,” said Dr. Jan Haller, senior scientist, process development, Novasep.

Dr. Haller continued, “We consider it very important to share this knowledge with scientific, manufacturing and regulatory communities to ensure that this compound is treated in a safe manner.”

“The work completed by Novasep regarding the Togni Reagent II will contribute to a more deliberate and responsible handling of the reagent used by so many research groups," said Professor Togni, professor of organometallic chemistry at the Laboratory of Inorganic Chemistry, ETH Zurich and inventor of the reagent.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Expands and Opens Subsidiary in India
Subsidiary to meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Friday, February 14, 2014
Novasep Attracts Top Talent to Complete its Executive Team
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Monday, January 20, 2014
Novasep Expands and Opens Subsidiary in India
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Monday, December 16, 2013
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!